Staying competitive in pharmacy management requires more than traditional approaches. It demands innovation, agility, and strategic decision-making based on actionable insights. This is where IntelRx emerges as a game-changer, revolutionizing pharmacoeconomic decision-making for pharmacy leaders and practice managers alike. Read on for three compelling case studies that explore the impact of IntelRx and the difference it can make in your practice.
The director of pharmacy at a leading practice witnessed a remarkable financial transformation within just one year. Thanks to the comprehensive data pulled from IntelRx and the insightful analysis provided by AC3 on payer-specific drug margins and utilization, this director reported an astounding $500,000 improvement in margins. This substantial turnaround didn't happen by chance; it was the result of informed decisions backed by data-driven insights.
At this practice, pegfilgrastim’s usage patterns underwent a significant evolution. Initially operating at a margin of -53%, IntelRx's insights guided this practice to switch their formulary and allowed them to see this margin increase to 14.5% within the span of a single year. Such a substantial improvement highlights the tangible impact of data-driven decision-making facilitated by IntelRx and AC3.
The transformation of pegfilgrastim’s margin serves as a testament to the effectiveness of IntelRx and AC3 in making the best clinical decisions and minimizing costs – for patients and the practice. This increase in margin not only boosted overall revenue but also laid the foundation for long-term sustainability and growth.
By harnessing the power of data-driven insights, practices are unlocking new possibilities for success. Whether it's optimizing drug utilization, negotiating favorable contracts with payers, or identifying opportunities for margin improvement, IntelRx and AC3 are empowering pharmacy leaders to make informed decisions that drive tangible results.
Underwater drugs represent a significant challenge for healthcare practices across the board. When the reimbursement rates for certain medications fall below the cost of acquisition, practices find themselves operating at a loss. Over time, these losses can accumulate, eroding revenue and threatening the sustainability of the practice.
The scenario faced by another practice is all too familiar in the world of pharmacy management. Despite providing essential medications to patients, they were hemorrhaging money due to underwater drugs—until data came to the rescue.
Recognizing the need for a solution, this practice turned to its pharmaceutical data for answers. By conducting a thorough review of all drug codes across all payers, they identified a set of actionable codes to focus on. The reimbursement rates of these codes were below the acquisition costs. Armed with this insight, they approached their payer with a compelling case for adjustment.
The results were nothing short of remarkable. With minimal effort on their part, the practice successfully persuaded the payer to adjust the reimbursement rates for 80% of the requested codes. The impact was immediate and significant, resulting in substantial increases in reimbursement percentages for the affected medications.
In the case of underwater drugs, data serves as a guiding light, illuminating areas of inefficiency and loss. Armed with this insight, practice and pharmacy leaders can take proactive steps to address reimbursement discrepancies, negotiate more favorable terms with payers and suppliers, and ultimately improve the health of their practice.
To ensure long-term success, the practice continued to monitor reimbursement rates and track performance metrics. By staying vigilant, they will be able to identify and address any future instances of underwater drugs, further bolstering their resilience.
The director of pharmacy at a leading healthcare practice was able to analyze data with IntelRx and make informed choices that led away from drugs that were under-performing and in some cases underwater. Anemia is a frequent complication in cancer patients, and oncologists manage this condition through infusion pharmaceuticals.
By leveraging comprehensive data analytics provided by IntelRx and insightful analysis from AC3, this practice substituted one iron infusion pharmaceutical for another biosimilar drug with the same clinical outcome and saw an astounding improvement in margins, transitioning from a pre-rebate deficit of -5.25% to a robust pre-rebate 35.99% in just six months. This substantial turnaround wasn't coincidental; it was the result of strategic decisions informed by data-driven insights.
These case studies serve as compelling examples of the transformative power of pharmaceutical data. By leveraging actionable insights to identify and address revenue leaks, healthcare practices can reclaim lost revenue, improve profitability, and ensure long-term sustainability.
As the healthcare landscape continues to evolve, the importance of data-driven decision-making in pharmacy management cannot be overstated. By embracing platforms like IntelRx that provide access to comprehensive pharmaceutical data and partnering with AC3, practices can position themselves for success in an increasingly competitive and complex environment.
It's time to unlock the full potential of data and analytics and chart a course towards a future of sustainability in pharmacy practice. With the right tools and strategies in place, the possibilities are limitless.
Ready to see IntelRx for yourself? Request your personalized demo now.